Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Protective Effects of Bacillus amyloliquefaciens 40 Against Clostridium perfringens Infection in Mice

  • 2021-10-21
  • Frontiers in Nutrition 8
    • Zipeng Jiang
    • Wentao Li
    • W. Su
    • Chaoyue Wen
    • Tao Gong
    • Yu Zhang
    • Yizhen Wang
    • M. Jin
    • Zeqing Lu

Abstract

This study aimed to investigate the protective effects of Bacillus amyloliquefaciens (BA40) against Clostridium perfringens (C. perfringens) infection in mice. Bacillus subtilis PB6 was utilized as a positive control to compare the protective effects of BA40. In general, a total of 24 5-week-old male C57BL/6 mice were randomly divided into four groups, with six mice each. The BA40 and PB6 groups were orally dosed with resuspension bacteria (1 × 109 CFU/ml) once a day, from day 1 to 13, respectively. In the control and infected groups, the mice were orally pre-treated with phosphate-buffered saline (PBS) (200 μl/day). The mice in the infected groups, PB6 + infected group and BA40 + infected group, were orally challenged with C. perfringens type A (1 × 109 CFU/ml) on day 11, whereas the control group was orally dosed with PBS (200 μl/day). The results showed that the BA40 group ameliorated intestinal structure damage caused by the C. perfringens infection. Furthermore, the inflammatory responses detected in the infected groups which include the concentrations of IL-1β, TNF-α, IL-6, and immunoglobulin G (IgG) in the serum and secretory immunoglobulin (SigA) in the colon, and nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) activity in the jejunum, were also alleviated (P < 0.05) by BA40 treatment. Similarly, cytokines were also detected by quantitative PCR (qPCR) in the messenger RNA (mRNA) levels, and the results were consistent with the enzyme-linked immunosorbent assay (ELISA) kits. Additionally, in the infected group, the mRNA expression of Bax and p53 was increasing and the Bcl-2 expression was decreasing, which was reversed by BA40 and PB6 treatment (P < 0.05). Moreover, the intestinal microbiota imbalance induced by the C. perfringens infection was restored by the BA40 pre-treatment, especially by improving the relative abundance of Verrucomicrobiota (P < 0.05) and decreasing the relative abundance of Bacteroidetes (P < 0.05) in the phyla level, and the infected group increased the relative abundance of some pathogens, such as Bacteroides and Staphylococcus (P < 0.05) in the genus level. The gut microbiota alterations in the BA40 group also influenced the metabolic pathways, and the results were also compared. The purine metabolism, 2-oxocarboxylic acid metabolism, and starch and sucrose metabolism were significantly changed (P < 0.05). In conclusion, our results demonstrated that BA40 can effectively protect mice from C. perfringens infection.

Keywords: Bacillus amyloliquefaciens; Clostridium perfringens; immunity; metabolic pathways; mice; microbiota.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bacillus subtilis MB40Influence on Metabolic PathwaysBeneficial
Moderate
Bacillus subtilis MB40Normalized Apoptotic Marker ExpressionBeneficial
Moderate
Bacillus subtilis MB40Reduced Inflammatory ResponseBeneficial
Moderate
Bacillus subtilis MB40Reduced Intestinal DamageBeneficial
Moderate
Bacillus subtilis MB40Restored Intestinal Microbiota BalanceBeneficial
Large
Back to top